ConductScience.org, home

Comparison · NCT02656017-deaths

Metformin vs Placebo: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Metformin vs Placebo: deaths from any cause. Trial comparisons, record NCT02656017-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02656017-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 100.000000000000000006940.0727wilson
Risk in group 200.000000000000000006940.0741wilson
Risk difference, group 1 minus group 20-0.07410.0727newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Metformin
Participants will be started on 500 mg of metformin once daily, with the following scheduled dose titrations:~* Increase to 500mg twice daily at week 2~* Increase to 1000mg qAM, 500mg qPM at week 4~* Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~ * Increased titrations based on tolerability~Metformin: Monitoring of tolerability and symptoms.
049EG000
Group 2Placebo
Participants will be started on 500 mg of placebo once daily, with the following scheduled dose titrations:~* Increase to 500mg twice daily at week 2~* Increase to 1000mg qAM, 500mg qPM at week 4~* Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~ * Increased titrations based on tolerability~Placebo: Monitoring of tolerability and symptoms.
048EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Adverse event were data collected at 2, 4, and 6 weeks during the titration period and every 3 months thereafter through 26 months.

Source ClinicalTrials.gov

Trial

Title
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
NCT number
NCT02656017
Phases
PHASE2
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Lead sponsor
Kyongtae Ty Bae, M.D., Ph.D.
Results first posted
2022-08-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02656017-deaths